News Coverage 10.20.20 Share on Twitter Share on Facebook Share on LinkedIn The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement. Related Announcement PICI Hosts 2024 Spring Scientific Retreat Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes Announcement, From Bench to Fireside Episode Nine: Katie Campbell, PhD
Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes